Hightower Rylie M, Alexander Matthew S
University of Alabama at Birmingham Graduate School of Biomedical Sciences, Birmingham, Alabama, USA.
Department of Pediatrics, Division of Neurology at Children's of Alabama and University of Alabama at Birmingham, MCLM 464 Box 96, 1918 University Boulevard Birmingham, Alabama, 35294, USA.
Muscle Nerve. 2018 Jan;57(1):6-15. doi: 10.1002/mus.25953. Epub 2017 Sep 22.
Muscular dystrophy is defined as the progressive wasting of skeletal muscles that is caused by inherited or spontaneous genetic mutations. Next-generation sequencing has greatly improved the accuracy and speed of diagnosis for different types of muscular dystrophy. Advancements in depth of coverage, convenience, and overall reduced cost have led to the identification of genetic modifiers that are responsible for phenotypic variability in affected patients. These genetic modifiers have been postulated to explain key differences in disease phenotypes, including age of loss of ambulation, steroid responsiveness, and the presence or absence of cardiac defects in patients with the same form of muscular dystrophy. This review highlights recent findings on genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies based on animal and clinical studies. These genetic modifiers hold great promise to be developed into novel therapeutic targets for the treatment of muscular dystrophies. Muscle Nerve 57: 6-15, 2018.
肌肉萎缩症被定义为由遗传或自发基因突变引起的骨骼肌进行性萎缩。新一代测序技术极大地提高了不同类型肌肉萎缩症诊断的准确性和速度。覆盖深度、便利性的提升以及总体成本的降低,使得人们能够识别出导致受影响患者表型变异的基因修饰因子。这些基因修饰因子被认为可以解释疾病表型的关键差异,包括行走能力丧失的年龄、对类固醇的反应性以及相同类型肌肉萎缩症患者是否存在心脏缺陷。本综述重点介绍了基于动物和临床研究在杜兴氏和面肩肱型肌肉萎缩症基因修饰因子方面的最新发现。这些基因修饰因子极有希望被开发成为治疗肌肉萎缩症的新型治疗靶点。《肌肉与神经》57: 6 - 15, 2018年。